| |
Alios BioPharma Presents Data on its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C
|
| |
| |
- Nucleotide Analog AL-335 to Enter Phase 1 Clinical Trials in 4Q/2014 -
South San Francisco, CA - September 15, 2014 -Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, presented the preclinical profile of one of its wholly-owned anti-hepatitis C virus (HCV) nucleotides (AL-335) at the American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL) 2014 Special Conference on Hepatitis C on September 13thin New York City. Based upon the favorable data presented in the poster session, along with additional preclinical studies, Alios intends to advance AL-335 into Phase 1 clinical trials in the fourth quarter of 2014.
The AASLD/EASL poster presented preclinical data of AL-335, a novel uridine nucleotide analog. The goal of the current study was to evaluate the antiviral activity and selectivity of AL-335. Results from the study showed that AL-335 demonstrates potent inhibition of HCV in the cell-based replicon assay across genotypes. Other positive data showed that the AL-335 NTP is a potent inhibitor of the HCV NS5B polymerase and functions as a chain terminator, and shows high selectivity for the viral polymerase and not human polymerases. In addition, both in cells and in vivo, AL-335 was shown to metabolize to provide very high levels of the corresponding AL-335 NTP, which has a long in vivo half-life.
Nucleotides have become an important component of interferon-free combination therapy for patients with chronic hepatitis C (CHC) and there are currently few representatives of this important class of compounds advancing clinically. The discovery and development of safe and efficacious nucleotide analogs remains an important need for the treatment of CHC. In addition to AL-335, Alios is advancing AL-516, a purine nucleotide analog and its second wholly-owned anti-HCV nucleotide, through preclinical development towards human clinical trials in 2015.
"Although there has been tremendous progress in the treatment of chronic hepatitis C, new treatment alternatives are still needed," commented Dr. Lawrence M. Blatt, President and Chief Executive Officer of Alios. "The Alios purine and pyrimidine nucleotides AL-516 and AL-335 offer the potential for combination therapy that could be effective against all HCV genotypes, greatly simplifying therapy."
About Alios' Anti-HCV Nucleotides (AL-335 and AL-516)
AL-335 and AL-516 are nucleotide analog polymerase inhibitors, a class of compounds that has emerged as a key component of interferon-free combination regimens used in the treatment of chronic hepatitis C. As substrates of the HCV polymerase NS5B, this class of compounds has demonstrated high in vitro potency and good clinical efficacy, with a high barrier to the development of resistance. AL-335 is a uridine based nucleotide analog and AL-516 is a guanosine based nucleotide analog. Both are novel compounds that have demonstrated desirable profiles in preclinical studies and have the potential to be used in combination to create an all oral, fixed-dose, pan-genotypic, once daily, short duration solution for patients with chronic hepatitis C. AL-335 is expected to enter clinical development in Q4 2014. Both AL-335 and AL-516 are wholly owned by Alios BioPharma.
About Alios BioPharma
Alios BioPharma is a clinical stage biopharmaceutical company in South San Francisco, CA that is developing novel antiviral therapies for the treatment of viral diseases. The Alios virology discovery and development platform consists of a proprietary chemical library of nucleoside analogs as well as novel, proprietary virology-based screening systems. Alios is developing a portfolio of potential therapeutics for viral infections including RSV, influenza, rhinovirus, coronavirus and HCV. For more information please visit www.aliosbiopharma.com.
|
|
| |
| |
|
|
|
